Intravenous Immunoglobulin Treatment for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis
Top Cited Papers
Open Access
- 1 January 2003
- journal article
- clinical trial
- Published by American Medical Association (AMA) in Archives of Dermatology
- Vol. 139 (1) , 33-36
- https://doi.org/10.1001/archderm.139.1.33
Abstract
Research from JAMA Dermatology — Intravenous Immunoglobulin Treatment for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis — A Prospective Noncomparative Study Showing No Benefit on Mortality or ProgressionKeywords
This publication has 11 references indexed in Scilit:
- SCORTEN: A Severity-of-Illness Score for Toxic Epidermal NecrolysisJournal of Investigative Dermatology, 2000
- Death Receptors in Cutaneous Biology and DiseaseJournal of Investigative Dermatology, 2000
- Improving the outcome of patients with toxic epidermal necrolysis and Stevens-Johnson syndrome.Archives of Dermatology, 2000
- Inhibition of Toxic Epidermal Necrolysis by Blockade of CD95 with Human Intravenous ImmunoglobulinScience, 1998
- Toxic epidermal necrolysisThe Lancet, 1998
- Renal involvement in toxic epidermal necrolysisJournal of the American Academy of Dermatology, 1996
- Severe Adverse Cutaneous Reactions to DrugsNew England Journal of Medicine, 1994
- Drug-induced toxic epidermal necrolysis (Lyell syndrome) in patients infected with the human immunodeficiency virusJournal of the American Academy of Dermatology, 1992
- High-dose intravenous IgG treatment and renal functionThe Lancet, 1991
- Prediction of Creatinine Clearance from Serum CreatinineNephron, 1976